Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $33.6900 (1.03%) ($33.6900 - $33.6900) on Mon. May. 24, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.51% (three month average) | RSI | 23 | Latest Price | $33.6900(1.03%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TGTX declines -8.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) IWO(59%) ARKK(58%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.755% in a week (0% probabilities). VIXM(-45%) VXX(-38%) UUP(-18%) UNG(-3%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.755% (StdDev 3.51%) | Hourly BBV | 1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $13.93(-58.65%) | Resistance Level | $37.79 | 5 Day Moving Average | $33.26(1.29%) | 10 Day Moving Average | $34.23(-1.58%) | 20 Day Moving Average | $37.79(-10.85%) | To recent high | -33.1% | To recent low | 3.9% | Market Cap | $4.267b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |